The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 3.23% or $1.52 during the last trading session, reaching $48.59. About 224,573 shares traded or 38.24% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 13, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
The move comes after 8 months positive chart setup for the $1.26B company. It was reported on Apr, 13 by Barchart.com. We have $50.05 PT which if reached, will make NASDAQ:IFRX worth $37.86M more.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” on January 03, 2019, also Globenewswire.com with their article: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – GlobeNewswire” published on December 19, 2018, Globenewswire.com published: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on February 06, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS) – Nasdaq” published on February 06, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results – GlobeNewswire” with publication date: November 21, 2018.
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.26 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.